Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma

Leukemia

Volumn 21, Issue 12, 2007, Pages 2519-2526

  Neri, P ^a,b,c   Tassone, P ^a,b,c   Shammas, M ^a   Yasui, H ^b   Schipani, E ^d   Batchu, R B ^a   Blotta, S ^a,b,c   Prabhala, R ^a   Catley, L ^b   Hamasaki, M ^b   Hideshima, T ^b   Chauhan, D ^b   Jacob, G S ^e   Picker, D ^e   Venuta, S ^c   Anderson, K C ^b   Munshi, N C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Callisto Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATIPRIMOD; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; INTEGRIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW; CANCER CELL CULTURE; CELL ADHESION; CELL COUNT; CELL CYCLE REGULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MODULATION; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; SCID MOUSE; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 36348985499     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404912     Document Type: Article

References (38)

1. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607-612.
2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-937.
3. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001; 28: 577-582.
4. Barlogie B. Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience. Semin Hematol 2003; 40 (Suppl 4): 33-38.
5. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
6. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
7. Albrightson-Winslow CR, Brickson B, King A, Olivera D, Short B, Saunders C et al. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J Pharmacol Exp Ther 1990; 255: 382-387.
8. Hancock WW, Schmidbauer G, Badger AM, Kupiec-Weglinski JW. SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. Transplant Proc 1992; 24; 231-232.
9. Fan PY, Albrightson CR, Howell DN, Best C, Badger AM, Coffman TM. The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. J Am Soc Nephrol 1993; 3: 1680-1685.
10. Badger AM, Swift BA, Webb EF, Clark RK, Bugelski PJ, Griswold DE. Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression. Int J Immunopharmacol 1993; 15: 343-352.
11. High WB, Bugelski PJ, Nichols ME, Swift BA, Solleveld HA, Badger AM. Effects of a novel azaspirane (SK&F 105685) on arthritic lesions in the adjuvant Lewis rat: Attenuation of the inflammatory process and preservation of skeletal integrity. J Rheumatol 1994; 21: 476-483.
12. Bradbeer JN, Kapadia RD, Sarkar SK, Zhao H, Stroup GB, Swift BA et al. Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. Arthritis Rheum 1996; 39 504-514.
13. Badger AM, Newman-Tarr TM, Satterfield JL. Selective immunomodulatory activity of SK&F 106615, a macrophage-targeting antiarthritic compound, on antibody and cellular responses in rats and mice. Immunopharmacology 1997; 37: 53-61.
14. Handler JA, Badger A, Genell CA, Klinkner AM, Kassis S, Waites CR et al. Selective inhibition of phospholipases by atiprimod, a macrophage targeting antiarthritic compound. Toxicol Appl Pharmacol 1999; 159: 9-17.
15. Shailubhai K, Dheer S, Picker D, Kaur G, Sausville EA, Jacob GS. Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. J Exp Ther Oncol 2004; 4: 267-279
16. Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005; 105 4470-4476.
17. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D et al. Atiprfmod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005; 93: 70-80.
18. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W et al. Gp1-30 and ras mediated signaling in human plasma cell line INA-6: A cytokine-regulated tumor model for plasmacytoma. Hematol J 2001; 2: 42-53.
19. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31-36.
20. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
21. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997; 90: 754-765.
22. Schipani E, Lanske B, Hunzelman J, Luz A, Kovacs CS, Lee K et al. Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci USA 1997; 94: 13689-13694.
23. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005; 106: 713-716.
24. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251-4258.
25. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229-1237.
26. Sieff CA. Biology and clinical aspects of the hematopoietic growth factors. Annu Rev Med 1990; 41: 483-496.
27. Anderson K. Advances in the biology of multiple myeloma: Therapeutic applications. Semin Oncol 1999; 26 (Suppl 13): S10-S22.
28. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003; 194: 164-176.
29. Gupta S. Molecular steps of tumor necrosis factor receptor-mediated apoptosis. Curr Mol Med 2001; 1: 317-324.
30. Bharti AC, Aggarwal BB. Ranking the role of RANK ligand in apoptosis. Apoptosis 2004; 9: 677-690.
31. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
32. Sanz-Rodriguez F, Teixido J. VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma 2001; 41: 239-245.
33. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38: 71-81.
34. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol 2005; 18: 509-524.
35. Callander NS, Roadman GD. Myeloma bone disease. Semin Hematol 2001; 38: 276-285.
36. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32: 290-292.
37. Wozney JM. Bone morphogenetic proteins. Prog Growth Factor Res 1989; 1: 267-280.
38. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-2098.